Page last updated: 2024-12-05
hexamethylcyclotrisiloxane
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 10914 |
| CHEMBL ID | 3182063 |
| CHEBI ID | 189167 |
| SCHEMBL ID | 29235 |
| MeSH ID | M0081928 |
Synonyms (44)
| Synonym |
|---|
| c6h18o3si3 |
| AKOS008901190 |
| dimethylsiloxane cyclic trimer |
| hexamethylcyclotrisiloxane , |
| cyclotrisiloxane, hexamethyl- |
| 541-05-9 |
| 2,2,4,4,6,6-hexamethyl-1,3,5,2,4,6-trioxatrisilinane |
| hexamethylcyclotrisiloxane, 98% |
| NCGC00164098-01 |
| dc 246 |
| ai3-62005 |
| ccris 1326 |
| ls 8120 |
| sdk 10 |
| einecs 208-765-4 |
| inchi=1/c6h18o3si3/c1-10(2)7-11(3,4)9-12(5,6)8-10/h1-6h3 |
| htdjpcnnepuooq-uhfffaoysa- |
| H0725 |
| tox21_303233 |
| dtxcid307185 |
| cas-541-05-9 |
| NCGC00257091-01 |
| unii-epv75l8o0r |
| cyclotrisiloxane, 2,2,4,4,6,6-hexamethyl- |
| ec 208-765-4 |
| epv75l8o0r , |
| FT-0627018 |
| S09550 |
| SCHEMBL29235 |
| J-200100 , |
| 2,2,4,4,6,6-hexamethyl-1,3,5,2,4,6-trioxatrisilinane # |
| ch7260 |
| CHEMBL3182063 |
| mfcd00005943 |
| hexamethylcyclotrisiloxane, analytical standard |
| Q26840948 |
| AS-14775 |
| CHEBI:189167 |
| H11267 |
| 2-(boc-amino)-2-(4-hydroxyphenyl)aceticacid |
| A923449 |
| 25084-99-5 |
| DTXSID501337639 |
| hexamethyl-1,3,5,2,4,6-trioxatrisilinane |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| organosilicon compound | An organosilicon compound is a compound containing at least one carbon-silicon bond. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (2)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 0.4898 | 0.0002 | 29.3054 | 16,493.5996 | AID743075 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 0.0087 | 0.0010 | 24.5048 | 61.6448 | AID743215 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Research
Studies (11)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (18.18) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 42.40
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (42.40) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||